Craft
AroCell

AroCell

Revenue

KR12 M

FY, 2021

Market Capitalization

KR58.3 M

2022-09-23

AroCell Summary

Company summary

Overview
AroCell AB is an in vitro diagnostics company focusing on the monitoring of hematological malignancies, breast cancer, and other solid tumors. It is involved in the development, manufacture, and sale of products for the measurement of human Thymidine Kinase 1 (TK1) concentration in blood.
Type
Public
Founded
2003
HQ
Uppsala, SE | view all locations
Website
https://arocell.com/
Cybersecurity rating
Sectors

Key people

  • Karin Eriksson-Widblom

    Karin Eriksson-Widblom, Director

    • Peter Löwendahl

      Peter Löwendahl, Senior Director Regulatory Affairs Director

      • Eva Nordström

        Eva Nordström, Director

        • Michael Brobjer

          Michael Brobjer, CEO

          LocationsView all

          1 location detected

          • Uppsala, Uppsala län HQ

            Sweden

            Virdings allé 32B

          AroCell Financials

          Summary financials

          Revenue (Q2, 2022)
          kr6.3M
          Gross profit (Q2, 2022)
          (kr1.9M)
          Net income (Q2, 2022)
          (kr16.0M)
          Cash (Q2, 2022)
          kr69.8M
          EBIT (Q2, 2022)
          (kr16.0M)
          Enterprise value
          ($11.5M)

          Footer menu